LU92595I2 - Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium - Google Patents

Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium Download PDF

Info

Publication number
LU92595I2
LU92595I2 LU92595C LU92595C LU92595I2 LU 92595 I2 LU92595 I2 LU 92595I2 LU 92595 C LU92595 C LU 92595C LU 92595 C LU92595 C LU 92595C LU 92595 I2 LU92595 I2 LU 92595I2
Authority
LU
Luxembourg
Prior art keywords
simeprévir
sodium
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
LU92595C
Other languages
English (en)
French (fr)
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34831013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92595(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0400199A external-priority patent/SE0400199D0/xx
Priority claimed from SE0401288A external-priority patent/SE0401288D0/xx
Priority claimed from SE0402562A external-priority patent/SE0402562D0/xx
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of LU92595I2 publication Critical patent/LU92595I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
LU92595C 2004-01-30 2014-11-11 Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium LU92595I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0400199A SE0400199D0 (sv) 2004-01-30 2004-01-30 HCV Protease inhbitors
SE0401288A SE0401288D0 (sv) 2004-05-19 2004-05-19 HCV NS-3 Serine Protease Inhbitors
SE0402562A SE0402562D0 (sv) 2004-10-22 2004-10-22 HCV Protease Inhbitors
PCT/SE2005/000096 WO2005073216A2 (en) 2004-01-30 2005-01-28 Hcv ns-3 serine protease inhibitors

Publications (1)

Publication Number Publication Date
LU92595I2 true LU92595I2 (fr) 2015-11-02

Family

ID=34831013

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92595C LU92595I2 (fr) 2004-01-30 2014-11-11 Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium

Country Status (32)

Country Link
US (5) US7671032B2 (sr)
EP (2) EP1713823B1 (sr)
JP (4) JP5248783B2 (sr)
KR (3) KR20120090077A (sr)
AR (2) AR048401A1 (sr)
AT (2) ATE448243T1 (sr)
AU (2) AU2005207816C1 (sr)
BR (2) BRPI0506948B1 (sr)
CA (2) CA2552319C (sr)
CR (2) CR8539A (sr)
CY (1) CY1109779T1 (sr)
DE (2) DE602005017582D1 (sr)
DK (2) DK1713823T3 (sr)
EA (2) EA014584B1 (sr)
EC (2) ECSP066726A (sr)
ES (2) ES2342944T3 (sr)
HR (1) HRP20100048T1 (sr)
IL (2) IL176848A (sr)
LU (1) LU92595I2 (sr)
MY (2) MY146349A (sr)
NI (1) NI200600168A (sr)
NL (1) NL300703I2 (sr)
NO (1) NO341392B1 (sr)
NZ (2) NZ548740A (sr)
PL (2) PL1713823T3 (sr)
PT (1) PT1713823E (sr)
RS (1) RS51243B (sr)
SI (1) SI1713823T1 (sr)
TW (2) TWI367211B (sr)
UA (2) UA84189C2 (sr)
WO (2) WO2005073216A2 (sr)
ZA (1) ZA200607214B (sr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
NZ544076A (en) * 2003-05-21 2009-04-30 Boehringer Ingelheim Int Hepatitis C inhibitor compounds
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
DE602005017582D1 (en) * 2004-01-30 2009-12-24 Medivir Ab Hcv ns-3 serine protease inhibitoren
BRPI0509467A (pt) * 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA019888B1 (ru) * 2005-07-25 2014-07-30 Интермьюн, Инк. Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза
TWI383980B (zh) * 2005-07-29 2013-02-01 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑
PE20070210A1 (es) * 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
ES2360417T3 (es) * 2005-07-29 2011-06-03 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
JP5230415B2 (ja) 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ Ｃ型肝炎ウイルスの大員環状阻害剤
EP1912997B1 (en) * 2005-07-29 2011-09-14 Tibotec Pharmaceuticals Macrocyclic inhibitors of hepatitis c virus
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
WO2007014921A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
JP2009502845A (ja) * 2005-07-29 2009-01-29 メディヴィル・アクチボラグ Ｃ型肝炎ウイルスの大環状インヒビター
MY142972A (en) 2005-07-29 2011-01-31 Tibotec Pharm Ltd Macrocyclic inhibitors of hepatitis c virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
MY144607A (en) * 2005-07-29 2011-10-14 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
ATE493409T1 (de) 2005-10-11 2011-01-15 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7655394B2 (en) * 2005-10-28 2010-02-02 Boehringer Ingelheim International Gmbh Hepatitis C virus NS2/3 activity assay
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
NZ574605A (en) 2006-07-13 2011-11-25 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP1881002A1 (en) * 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
EP1881001A1 (en) * 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
EP2518494A3 (en) * 2006-08-09 2013-11-20 Sumitomo Bakelite Company, Ltd. Sugar chain- capturing substance and use thereof
CN101573370B (zh) 2006-10-10 2013-09-11 美迪维尔公司 Hcv核苷类抑制剂
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008059046A1 (en) * 2006-11-17 2008-05-22 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
EP2121681B1 (en) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2675142C (en) * 2007-01-26 2014-08-19 Merck Frosst Canada Ltd. Fused aromatic difluoromethanephosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
CN101589040A (zh) * 2007-02-01 2009-11-25 泰博特克药品有限公司 Hcv巨环抑制剂的多晶形
EP2121674B1 (en) 2007-02-01 2010-05-12 Tibotec Pharmaceuticals Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
EP2118091B1 (en) * 2007-02-08 2015-04-15 Janssen Sciences Ireland UC Pyrimidine substituted macrocyclic hcv inhibitors
DK2111396T3 (da) * 2007-02-08 2013-11-04 Janssen R & D Ireland HCV-Inhiberende makrocykliske phenylcarbamater
US8435984B2 (en) 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
CN101679483A (zh) * 2007-03-23 2010-03-24 先灵公司 作为hcv ns3-蛋白酶抑制剂的酰肼-肽
KR20100027134A (ko) 2007-05-10 2010-03-10 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 펩티드 억제제
CA2700383A1 (en) 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
CN102026544A (zh) * 2007-11-14 2011-04-20 益安药业 大环四唑基丙型肝炎病毒丝氨酸蛋白酶抑制剂
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8283309B2 (en) * 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
BRPI0908021A2 (pt) * 2008-02-04 2015-07-21 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
JP5490778B2 (ja) 2008-03-20 2014-05-14 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物
BRPI0911260A2 (pt) 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009322393B2 (en) 2008-12-03 2017-02-02 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
WO2010065681A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CN102245599B (zh) 2008-12-10 2014-05-14 艾其林医药公司 作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2382198T3 (pl) 2008-12-23 2013-11-29 Janssen Pharmaceuticals Inc Sposoby i półprodukty do otrzymywania makrocyklicznego inhibitora proteazy HCV
CN104478868A (zh) 2009-02-27 2015-04-01 奥索-麦克尼尔-詹森药品公司 Hcv大环抑制剂的无定形盐
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.
JP2012523419A (ja) 2009-04-08 2012-10-04 イデニク プハルマセウティカルス，インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
WO2011113859A1 (en) * 2010-03-16 2011-09-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
SG10201506652QA (en) 2010-04-13 2015-10-29 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
AR082619A1 (es) 2010-08-13 2012-12-19 Hoffmann La Roche Inhibidores del virus de la hepatitis c
SG189985A1 (en) 2010-10-26 2013-06-28 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
AR085352A1 (es) * 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103732242A (zh) 2011-06-23 2014-04-16 迪格纳生物技术公司 用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
EP2758386A1 (en) 2011-09-22 2014-07-30 Janssen Pharmaceuticals, Inc. Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
MX2014003705A (es) 2011-10-10 2014-07-22 Hoffmann La Roche Compuestos antivirales.
BR112014013972A8 (pt) 2011-12-16 2017-06-13 Hoffmann La Roche inibidores de hcv nssa
PT2794629T (pt) 2011-12-20 2017-07-20 Riboscience Llc Derivados de nucleósidos substituídos em 2¿-4¿-difluor-2¿-metilo, como inibidores da replicação do arn de vhc (vírus da hepatite c)
BR112014015066A2 (pt) 2011-12-20 2017-06-13 Hoffmann La Roche derivados de nucleosídeos 4'azido-3'-flúor substituídos como inibidores de replicação do rna de hcv
EP2802574A4 (en) 2012-01-12 2015-06-24 Rfs Pharma Llc INHIBITORS OF HCV NS3 PROTEASE
WO2013124335A1 (en) 2012-02-24 2013-08-29 F. Hoffmann-La Roche Ag Antiviral compounds
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CA2892589A1 (en) 2013-01-23 2014-07-31 F. Hoffmann-La Roche Ag Antiviral triazole derivatives
RU2015136256A (ru) 2013-03-05 2017-04-10 Ф. Хоффманн-Ля Рош Аг Противовирусные соединения
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
AU2014236502A1 (en) 2013-03-14 2015-10-01 Achillion Pharmaceuticals, Inc. Processes for producing Sovaprevir
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
KR102241198B1 (ko) 2013-05-16 2021-04-15 리보사이언스 엘엘씨 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체
WO2014193663A1 (en) 2013-05-16 2014-12-04 Riboscience Llc 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
TWI860279B (zh) 2017-09-21 2024-11-01 美商里伯賽恩斯有限責任公司 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物
US11480714B2 (en) 2017-10-04 2022-10-25 University Of Florida Research Foundation, Inc. Methods and compositions for improved comfort contact lens
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US5340801A (en) * 1991-05-08 1994-08-23 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having cholecystokinin and gastrin antagonistic properties
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6900238B1 (en) * 1995-12-07 2005-05-31 The Scripps Research Institute HIV protease inhibitors
PL194025B1 (pl) 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
PT1003775E (pt) 1997-08-11 2005-07-29 Boehringer Ingelheim Ca Ltd Peptidos inibidores da hepatite c
WO1999051613A1 (en) 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
JPH11292840A (ja) * 1998-04-06 1999-10-26 Soyaku Gijutsu Kenkyusho:Kk ノルスタチン誘導体又はその塩
AU4393399A (en) 1998-06-24 2000-01-10 Chugai Seiyaku Kabushiki Kaisha Hcv-derived rna polymerase gene
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19915178A1 (de) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
GB9925955D0 (en) * 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
EP1252178A1 (en) * 1999-12-03 2002-10-30 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU2001251165A1 (en) 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6846802B2 (en) * 2000-04-05 2005-01-25 Schering Corporation Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SK288064B6 (sk) * 2000-07-21 2013-04-03 Merck Sharp & Dohme Corp. Peptide compounds, pharmaceutical compositions comprising them and their use
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
ATE327246T1 (de) 2000-11-20 2006-06-15 Bristol Myers Squibb Co Hepatitis c tripeptid inhibitoren
US6911428B2 (en) * 2000-12-12 2005-06-28 Schering Corporation Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
US6909000B2 (en) * 2001-07-11 2005-06-21 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
EP2402009A1 (en) 2001-10-24 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus NS3-NS4A protease, incorporating a fused ring system
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
MXPA04007163A (es) 2002-01-23 2004-10-29 Schering Corp Compuestos de prolina como inhibidores de la proteasa serina ns3 para utilizarse en el tratamiento de la infeccion por el virus de la hepatitis c.
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
TW200403236A (en) 2002-04-11 2004-03-01 Vertex Pharma Inhibitors or serine proteases, particularly HCV NS3-NS4A protease
US6878722B2 (en) 2002-05-20 2005-04-12 Bristol-Myers Squibb Company Substituted cycloalkyl P1′ hepatitis C virus inhibitors
EP1506172B1 (en) * 2002-05-20 2011-03-30 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2003099316A1 (en) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CA2490950A1 (en) * 2002-07-01 2004-01-08 Pharmacia & Upjohn Company Llc Inhibitors of hcv ns5b polymerase
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2004026896A2 (en) 2002-09-23 2004-04-01 Medivir Ab Hcv ns-3 serine protease inhibitors
EP1408031A1 (en) * 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
DE60318954T2 (de) 2002-10-29 2009-01-22 Boehringer Ingelheim International Gmbh Inhibitor-resistente hcv-ns3-protease
JP2007524576A (ja) 2003-02-07 2007-08-30 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状のｃ型肝炎セリンプロテアーゼ阻害剤
CA2516018C (en) 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
WO2004093915A1 (en) 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis c viral protease inhibitors
TW200510391A (en) 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ES2320771T3 (es) 2003-04-16 2009-05-28 Bristol-Myers Squibb Company Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
WO2004093798A2 (en) 2003-04-18 2004-11-04 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
NZ544076A (en) 2003-05-21 2009-04-30 Boehringer Ingelheim Int Hepatitis C inhibitor compounds
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
WO2005037826A1 (en) * 2003-10-17 2005-04-28 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
DE602005017582D1 (en) 2004-01-30 2009-12-24 Medivir Ab Hcv ns-3 serine protease inhibitoren
TWI383980B (zh) 2005-07-29 2013-02-01 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
MY142972A (en) 2005-07-29 2011-01-31 Tibotec Pharm Ltd Macrocyclic inhibitors of hepatitis c virus
JP2009502845A (ja) 2005-07-29 2009-01-29 メディヴィル・アクチボラグ Ｃ型肝炎ウイルスの大環状インヒビター
JP5230415B2 (ja) 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ Ｃ型肝炎ウイルスの大員環状阻害剤
EP1912997B1 (en) 2005-07-29 2011-09-14 Tibotec Pharmaceuticals Macrocyclic inhibitors of hepatitis c virus
WO2007014921A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
MY144607A (en) 2005-07-29 2011-10-14 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus

Also Published As

Publication number Publication date
AU2005207816C1 (en) 2015-05-07
CR8539A (es) 2009-02-23
AU2005207815B2 (en) 2011-08-04
ATE461209T1 (de) 2010-04-15
UA84189C2 (en) 2008-09-25
CA2552317C (en) 2013-12-10
US10172846B2 (en) 2019-01-08
BRPI0506948B1 (pt) 2018-09-18
TW200538449A (en) 2005-12-01
PL1713822T3 (pl) 2010-08-31
JP2014055161A (ja) 2014-03-27
TWI361195B (en) 2012-04-01
EP1713822A2 (en) 2006-10-25
KR101217036B1 (ko) 2013-01-02
JP2007524670A (ja) 2007-08-30
ECSP066725A (es) 2006-12-29
DK1713822T3 (da) 2010-07-19
CY1109779T1 (el) 2014-09-10
US20070161574A1 (en) 2007-07-12
ATE448243T1 (de) 2009-11-15
KR101159575B1 (ko) 2012-07-06
PT1713823E (pt) 2010-02-02
HRP20100048T1 (hr) 2010-04-30
NO20063851L (no) 2006-08-29
US7608590B2 (en) 2009-10-27
TW200538450A (en) 2005-12-01
ES2336009T8 (es) 2014-11-05
WO2005073216A3 (en) 2005-10-06
DK1713823T3 (da) 2010-03-08
WO2005073216A2 (en) 2005-08-11
NI200600168A (es) 2016-02-11
US20070203072A1 (en) 2007-08-30
US20100166706A1 (en) 2010-07-01
IL176921A0 (en) 2006-12-10
MY153011A (en) 2014-12-31
KR20060126567A (ko) 2006-12-07
UA84050C2 (en) 2008-09-10
JP4902361B2 (ja) 2012-03-21
JP2007519716A (ja) 2007-07-19
IL176921A (en) 2012-03-29
JP5248783B2 (ja) 2013-07-31
AU2005207816A1 (en) 2005-08-11
JP5795619B2 (ja) 2015-10-14
NL300703I2 (nl) 2017-07-20
KR20070009571A (ko) 2007-01-18
NZ548740A (en) 2010-06-25
IL176848A (en) 2015-07-30
WO2005073195A2 (en) 2005-08-11
IL176848A0 (en) 2006-10-31
MY146349A (en) 2012-08-15
ES2342944T3 (es) 2010-07-19
EA012410B1 (ru) 2009-10-30
CA2552319C (en) 2012-08-21
AU2005207816B2 (en) 2011-04-14
ES2336009T3 (es) 2010-04-07
EP1713823A2 (en) 2006-10-25
JP2011140488A (ja) 2011-07-21
HK1100881A1 (en) 2007-09-28
US20100003216A1 (en) 2010-01-07
US20170196849A1 (en) 2017-07-13
EA200601400A1 (ru) 2007-02-27
TWI367211B (en) 2012-07-01
EA200601399A1 (ru) 2006-12-29
NZ548739A (en) 2010-10-29
DE602005019979D1 (en) 2010-04-29
CR8540A (es) 2009-01-16
PL1713823T3 (pl) 2010-04-30
RS51243B (sr) 2010-12-31
KR20120090077A (ko) 2012-08-16
AR048401A1 (es) 2006-04-26
US7671032B2 (en) 2010-03-02
ECSP066726A (es) 2006-12-29
CA2552319A1 (en) 2005-08-11
WO2005073195A3 (en) 2005-09-29
SI1713823T1 (sl) 2010-04-30
AR047793A1 (es) 2006-02-22
BRPI0506948A (pt) 2007-06-12
NO341392B1 (no) 2017-10-30
EP1713823B1 (en) 2009-11-11
HK1104044A1 (en) 2008-01-04
AU2005207815A1 (en) 2005-08-11
EA014584B1 (ru) 2010-12-30
EP1713822B1 (en) 2010-03-17
DE602005017582D1 (en) 2009-12-24
BRPI0506945A (pt) 2007-06-12
CA2552317A1 (en) 2005-08-11
ZA200607214B (en) 2008-04-30

Similar Documents

Publication Publication Date Title
LU92595I2 (fr) Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
LU92550I2 (fr) Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables
LU92684I2 (fr) Fidaxomicine ou son sel pharmaceutiquement acceptable
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
LU92182I2 (fr) Dapagliflozine et ses sels pharmaceutiquement acceptables
EP1608964A4 (en) CREATING AN EXPRESSION PROFILE OF TUMORS
BE2014C011I2 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
ITUD20030092A1 (it) Protesi per l'articolazione della spalla.
EP1816988A4 (en) SIGMOID-NOTCH IMPLANT
NO20032909D0 (no) Glukopyranosyloksypyrazolderivater samt medikamentell anvendelse derav
NO2012017I2 (no) Azilsartan medoxomil og farmasøytisk akseptabelt salt derav, innbefattende kaliumsalt
DK1575618T3 (da) Dispergerbare farmaceutiske kombinationer
NO20042140L (no) Terapeutiske quionolonforbindelser med 5-HT anatagonistiske egenskaper
LU92826I2 (fr) Lubiprostone, incluant les sels pharmaceutiquementacceptables, les esters ou les amides de la lubip rostone
DK1765859T3 (da) Annexiner, derivater deraf og annexin-cys varianter samt terapeutiske og diagnostiske anvendelser deraf
BR0300119B1 (pt) composiÇço aquosa.
DE602004007387D1 (de) 5-substituierte chinazolinonderivate
DE602005025450D1 (de) Homokinetisches gelenk
EP2100588A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST ALOPEY
ZA200409624B (en) Pharmaceutical salts of reboxetine
ITMI20042099A1 (it) Estratti di trifoglio per la preparazione di agenti anti-afidi
FR2886642B1 (fr) Sels alcalino-terreux d'irbesartan et leur preparation
EP1866071A4 (en) PERMETHYLATION OF OLIGOSACCHARIDES